GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » Change In Working Capital

Albert Labs International (XCNQ:ABRT) Change In Working Capital : C$-0.31 Mil (TTM As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International Change In Working Capital?

Albert Labs International's change in working capital for the quarter that ended in Sep. 2023 was C$0.00 Mil.

Albert Labs International's change in working capital for the fiscal year that ended in Dec. 2022 was C$-0.54 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


Albert Labs International Change In Working Capital Historical Data

The historical data trend for Albert Labs International's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International Change In Working Capital Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Change In Working Capital
0.97 -0.54

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.27 - -0.03 -

Albert Labs International Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.31 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albert Labs International Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Albert Labs International's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Albert Labs International (XCNQ:ABRT) Business Description

Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines